skip to main content

Prostate Cancer — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardUrological CancersProstate CancerSCE Medical Oncology

Two patients with advanced renal-cell carcinoma are considered for tivozanib: one has stable Child-Pugh B cirrhosis and the other has Child-Pugh C cirrhosis. Which dosing statement matches the current UK SmPC?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: A — Use 1,340 micrograms every other day in Child-Pugh B and do not use tivozanib in Child-Pugh C

Explanation lettering: D = shown as A · A = shown as B · B = shown as C · C = shown as D

D is correct: tivozanib exposure rises about 2.6-fold in moderate hepatic impairment, so Child-Pugh B treatment is reduced to one 1,340-microgram capsule every other day; exposure rises about 4-fold in severe impairment, and tivozanib should not be used in Child-Pugh C. A ignores both exposure changes. B invents an 890-microgram hepatic schedule and still treats severe impairment. C changes cycle timing rather than the stated dose interval and treats Child-Pugh C, while E leaves moderate impairment unadjusted and also treats severe impairment.

Reference: Fotivda UK summary of product characteristics (Current UK SmPC, accessed 1 August 2026): https://www.medicines.org.uk/emc/product/8995/smpc